Edmond DE Rothschild Holding S.A. Acquires New Position in Baxter International Inc. $BAX

Edmond DE Rothschild Holding S.A. bought a new position in Baxter International Inc. (NYSE:BAX) in the second quarter, Holdings Channel reports. The institutional investor bought 2,437,052 shares of the medical instruments supplier’s stock, valued at approximately $51,958,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Baird Financial Group Inc. raised its stake in shares of Baxter International by 3.2% during the second quarter. Baird Financial Group Inc. now owns 52,436 shares of the medical instruments supplier’s stock worth $1,588,000 after acquiring an additional 1,604 shares in the last quarter. California State Teachers Retirement System grew its holdings in shares of Baxter International by 2.9% during the 2nd quarter. California State Teachers Retirement System now owns 649,463 shares of the medical instruments supplier’s stock valued at $19,666,000 after purchasing an additional 18,439 shares during the last quarter. Ameriprise Financial Inc. grew its holdings in shares of Baxter International by 1.3% during the 2nd quarter. Ameriprise Financial Inc. now owns 7,638,629 shares of the medical instruments supplier’s stock valued at $231,304,000 after purchasing an additional 97,687 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S raised its position in Baxter International by 21.4% in the 2nd quarter. BI Asset Management Fondsmaeglerselskab A S now owns 24,356 shares of the medical instruments supplier’s stock worth $737,000 after purchasing an additional 4,293 shares during the period. Finally, Captrust Financial Advisors raised its position in Baxter International by 5.5% in the 2nd quarter. Captrust Financial Advisors now owns 53,933 shares of the medical instruments supplier’s stock worth $1,633,000 after purchasing an additional 2,813 shares during the period. Hedge funds and other institutional investors own 90.19% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on BAX. Wells Fargo & Company boosted their price target on shares of Baxter International from $19.00 to $23.00 and gave the stock an “equal weight” rating in a research note on Friday, July 31st. Citigroup raised Baxter International from a “sell” rating to a “neutral” rating and raised their price objective for the company from $17.00 to $28.00 in a research note on Friday, July 31st. Barclays lifted their price objective on Baxter International from $25.00 to $27.00 and gave the stock an “overweight” rating in a report on Friday, May 1st. The Goldman Sachs Group increased their target price on Baxter International from $19.00 to $21.00 and gave the company a “neutral” rating in a report on Wednesday, July 15th. Finally, TD Cowen increased their target price on Baxter International from $20.00 to $24.00 and gave the company a “hold” rating in a report on Monday, July 27th. Two investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $22.45.

Baxter International Trading Up 2.6%

NYSE:BAX opened at $26.61 on Thursday. The company has a fifty day moving average of $23.40 and a 200 day moving average of $20.27. Baxter International Inc. has a 52 week low of $15.73 and a 52 week high of $30.00. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 1.39. The firm has a market capitalization of $13.76 billion, a P/E ratio of -12.86, a P/E/G ratio of 3.92 and a beta of 0.60.

Baxter International (NYSE:BAX) last announced its quarterly earnings results on Thursday, July 30th. The medical instruments supplier reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.19. The business had revenue of $2.96 billion during the quarter, compared to analysts’ expectations of $2.80 billion. Baxter International had a negative net margin of 9.27% and a positive return on equity of 16.57%. The firm’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.59 EPS. Baxter International has set its FY 2026 guidance at 1.950-2.150 EPS. On average, research analysts predict that Baxter International Inc. will post 2.04 earnings per share for the current year.

Baxter International Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 1st. Stockholders of record on Friday, August 28th will be issued a dividend of $0.01 per share. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.2%. The ex-dividend date is Friday, August 28th. Baxter International’s dividend payout ratio is currently -1.93%.

About Baxter International

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.